CareDx, Inc (NASDAQ:CDNA – Get Free Report) has received an average recommendation of “Moderate Buy” from the five ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $16.50.
A number of research analysts have recently commented on CDNA shares. Craig Hallum upped their price target on CareDx from $15.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, May 17th. The Goldman Sachs Group increased their target price on shares of CareDx from $10.00 to $14.00 and gave the stock a “buy” rating in a research report on Monday, May 13th. StockNews.com raised shares of CareDx from a “hold” rating to a “buy” rating in a research report on Thursday. Raymond James downgraded shares of CareDx from an “outperform” rating to a “market perform” rating in a report on Monday, May 13th. Finally, Stephens boosted their target price on shares of CareDx from $15.00 to $18.00 and gave the company an “overweight” rating in a report on Monday, May 13th.
View Our Latest Report on CDNA
CareDx Stock Performance
CareDx (NASDAQ:CDNA – Get Free Report) last released its earnings results on Thursday, May 9th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.18. CareDx had a negative net margin of 66.59% and a negative return on equity of 55.08%. The firm had revenue of $72.05 million during the quarter, compared to the consensus estimate of $63.63 million. Equities research analysts predict that CareDx will post -1.49 earnings per share for the current fiscal year.
Hedge Funds Weigh In On CareDx
Several hedge funds have recently bought and sold shares of the company. Swiss National Bank grew its position in shares of CareDx by 2.3% during the 3rd quarter. Swiss National Bank now owns 118,200 shares of the company’s stock valued at $827,000 after purchasing an additional 2,700 shares in the last quarter. Citigroup Inc. increased its stake in CareDx by 7.1% in the 3rd quarter. Citigroup Inc. now owns 132,560 shares of the company’s stock worth $928,000 after acquiring an additional 8,768 shares during the last quarter. WINTON GROUP Ltd purchased a new stake in shares of CareDx in the 3rd quarter valued at about $72,000. Acadian Asset Management LLC boosted its position in shares of CareDx by 25.6% during the 3rd quarter. Acadian Asset Management LLC now owns 441,422 shares of the company’s stock valued at $3,088,000 after acquiring an additional 89,966 shares during the last quarter. Finally, Dark Forest Capital Management LP purchased a new position in shares of CareDx during the third quarter worth about $152,000.
CareDx Company Profile
CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
Featured Articles
- Five stocks we like better than CareDx
- How to Invest in Biotech Stocks
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- Election Stocks: How Elections Affect the Stock Market
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.